company background image
VIVE

Vivesto OM:VIVE Stock Report

Last Price

kr0.78

Market Cap

kr417.5m

7D

10.9%

1Y

-73.4%

Updated

09 Aug, 2022

Data

Company Financials +
VIVE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

VIVE Stock Overview

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden.

Vivesto Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vivesto
Historical stock prices
Current Share Pricekr0.78
52 Week Highkr3.03
52 Week Lowkr0.57
Beta0.58
1 Month Change14.12%
3 Month Change-30.09%
1 Year Change-73.41%
3 Year Change-85.05%
5 Year Change-73.43%
Change since IPO-97.03%

Recent News & Updates

Shareholder Returns

VIVESE BiotechsSE Market
7D10.9%-1.9%-0.8%
1Y-73.4%-22.8%-23.9%

Return vs Industry: VIVE underperformed the Swedish Biotechs industry which returned -22.1% over the past year.

Return vs Market: VIVE underperformed the Swedish Market which returned -22% over the past year.

Price Volatility

Is VIVE's price volatile compared to industry and market?
VIVE volatility
VIVE Average Weekly Movement8.7%
Biotechs Industry Average Movement9.7%
Market Average Movement7.3%
10% most volatile stocks in SE Market12.7%
10% least volatile stocks in SE Market4.6%

Stable Share Price: VIVE is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: VIVE's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198819Christer Nordstedthttps://www.vivesto.com

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company’s products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer.

Vivesto Fundamentals Summary

How do Vivesto's earnings and revenue compare to its market cap?
VIVE fundamental statistics
Market Capkr417.52m
Earnings (TTM)-kr117.97m
Revenue (TTM)kr28.83m

14.5x

P/S Ratio

-3.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VIVE income statement (TTM)
Revenuekr28.83m
Cost of Revenuekr44.09m
Gross Profit-kr15.26m
Other Expenseskr102.71m
Earnings-kr117.97m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 25, 2022

Earnings per share (EPS)-0.22
Gross Margin-52.94%
Net Profit Margin-409.18%
Debt/Equity Ratio0%

How did VIVE perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is VIVE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VIVE?

Other financial metrics that can be useful for relative valuation.

VIVE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue12.2x
Enterprise Value/EBITDA-3.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does VIVE's PS Ratio compare to its peers?

VIVE PS Ratio vs Peers
The above table shows the PS ratio for VIVE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average22.1x
SANION Saniona
20.1xn/akr274.2m
ATORX Alligator Bioscience
20.8x101.6%kr408.1m
EGTX Egetis Therapeutics
19.3x77.3%kr802.6m
MVIR B Medivir
28.4x76.6%kr451.4m
VIVE Vivesto
14.5x60.3%kr417.5m

Price-To-Sales vs Peers: VIVE is good value based on its Price-To-Sales Ratio (14.5x) compared to the peer average (22.1x).


Price to Earnings Ratio vs Industry

How does VIVE's PE Ratio compare vs other companies in the SE Biotechs Industry?

Price-To-Sales vs Industry: VIVE is good value based on its Price-To-Sales Ratio (14.5x) compared to the Swedish Biotechs industry average (24.5x)


Price to Sales Ratio vs Fair Ratio

What is VIVE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VIVE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio14.5x
Fair PS Ratio6.7x

Price-To-Sales vs Fair Ratio: VIVE is expensive based on its Price-To-Sales Ratio (14.5x) compared to the estimated Fair Price-To-Sales Ratio (6.7x).


Share Price vs Fair Value

What is the Fair Price of VIVE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VIVE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VIVE's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Vivesto forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


60.3%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if VIVE's forecast earnings growth is above the savings rate (0.4%).

Earnings vs Market: Insufficient data to determine if VIVE's earnings are forecast to grow faster than the Swedish market

High Growth Earnings: Insufficient data to determine if VIVE's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: VIVE's revenue (60.3% per year) is forecast to grow faster than the Swedish market (11% per year).

High Growth Revenue: VIVE's revenue (60.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VIVE's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Vivesto performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-10.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: VIVE is currently unprofitable.

Growing Profit Margin: VIVE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VIVE is unprofitable, and losses have increased over the past 5 years at a rate of 10.6% per year.

Accelerating Growth: Unable to compare VIVE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VIVE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.2%).


Return on Equity

High ROE: VIVE has a negative Return on Equity (-17.93%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Vivesto's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: VIVE's short term assets (SEK250.8M) exceed its short term liabilities (SEK39.4M).

Long Term Liabilities: VIVE's short term assets (SEK250.8M) exceed its long term liabilities (SEK4.3M).


Debt to Equity History and Analysis

Debt Level: VIVE is debt free.

Reducing Debt: VIVE has no debt compared to 5 years ago when its debt to equity ratio was 55.6%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VIVE has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: VIVE has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.3% each year


Discover healthy companies

Dividend

What is Vivesto current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate VIVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VIVE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VIVE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VIVE's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as VIVE has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Christer Nordstedt (60 yo)

0.083

Tenure

Dr. Christer Nordstedt, M.D., Ph D., serves as Acting Chief Executive Officer at Vivesto AB since July 21, 2022. He serves as Chairman of the Board at WntResearch AB since 2022.He is engaged as a consulta...


Leadership Team

Experienced Management: VIVE's management team is considered experienced (2.6 years average tenure).


Board Members

Experienced Board: VIVE's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20%.


Top Shareholders

Company Information

Vivesto AB's employee growth, exchange listings and data sources


Key Information

  • Name: Vivesto AB
  • Ticker: VIVE
  • Exchange: OM
  • Founded: 1988
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr417.522m
  • Shares outstanding: 538.04m
  • Website: https://www.vivesto.com

Number of Employees


Location

  • Vivesto AB
  • Gustav III:s Boulevard 46
  • 5th floor
  • Solna
  • Stockholm County
  • 169 73
  • Sweden

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/09 00:00
End of Day Share Price2022/08/09 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.